Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche Reports Positive Results In Breast Cancer Study

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
SAE Member Profile
 
Followed By 2
Posts 564
Boards Moderated 0
Alias Born 08/06/09
160x600 placeholder
Roche Approves Proposals for Board and Executive Committee Dow Jones News - 12/9/2019 2:50:00 AM
Roche Extends Tender Offer for Spark Therapeutics Dow Jones News - 12/9/2019 2:16:00 AM
FDA Approves Marketing of Roche Diagnostics MRSA Diagnostic Test Dow Jones News - 12/5/2019 1:10:00 PM
Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer Dow Jones News - 12/3/2019 7:21:00 PM
Genentech Gets FDA Priority Review for Risdiplam for Spinal Muscular Atrophy Dow Jones News - 11/25/2019 7:36:00 AM
FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture Dow Jones News - 11/19/2019 8:45:00 AM
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis Dow Jones News - 9/18/2019 6:40:00 AM
Genentech Receives FDA Accelerated Approval for Cancer Treatment Dow Jones News - 8/15/2019 4:36:00 PM
Roche Extends Offer Period for Spark Therapeutics Dow Jones News - 7/31/2019 1:48:00 AM
Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer Dow Jones News - 7/26/2019 10:46:00 AM
Roche Sales Boosted by New Drug Pipeline -- Update Dow Jones News - 7/25/2019 4:14:00 AM
Roche 1st Half Profit, Sales Grew; Raises Full-Year Sales Guidance Dow Jones News - 7/25/2019 1:46:00 AM
Sanofi Gets Exclusive Over-The-Counter Rights to Tamiflu in the US From Roche Dow Jones News - 7/23/2019 1:47:00 AM
AbbVie Says FDA Lifts Partial Hold on Phase 3 Trial Dow Jones News - 6/24/2019 9:38:00 AM
Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint Dow Jones News - 6/20/2019 7:37:00 PM
SAE   Thursday, 12/08/11 11:16:26 AM
Re: None
Post # of 138 
Roche Reports Positive Results In Breast Cancer Study

Roche Holding AG (ROG.VX) Thursday said the results of its pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer were positive, with a 6.1 month improvement in median progression free survival, from 12.4 months to 18.5 months.

MAIN FACTS:

- Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab.

- The study compared the combination of pertuzumab, Herceptin (trastuzumab) and docetaxel chemotherapy to Herceptin and docetaxel alone in people with previously untreated HER2-positive metastatic breast cancer (mBC).

- People who received pertuzumab in combination with Herceptin and chemotherapy experienced a 38 percent reduction in the risk of their disease worsening or death (progression-free survival, or PFS), (HR=0.62; p-value=<0.0001).

- The median PFS improved by 6.1 months from 12.4 months for Herceptin and chemotherapy to 18.5 months for pertuzumab, Herceptin and chemotherapy.

- Overall survival (OS) data are currently immature, with a trend in favour of the pertuzumab combination.

- No new safety signals were observed and adverse events were consistent with those seen in previous studies of pertuzumab and Herceptin, either in combination or alone.

- The results will be presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10 (Abstract # S5-5), and were featured in the official press program.

- Data were published yesterday in the online edition of the New England Journal of Medicine.

- Roche has submitted a Biologics License Application for pertuzumab to the U.S. Food and Drug Administration for people with previously untreated, HER2-positive metastatic breast cancer and a Marketing Authorization Application to the European Medicines Agency in the same indication.

-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist